RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immunovia AB (publ) - Stock

Immunovia AB (publ) Equity 2024

Immunovia AB (publ) Equity

66.99 M SEK

Ticker

IMMNOV.ST

ISIN

SE0006091997

WKN

A2AG0F

In 2024, Immunovia AB (publ)'s equity was 66.99 M SEK, a -72.52% increase from the 243.8 M SEK equity in the previous year.

Immunovia AB (publ) Aktienanalyse

What does Immunovia AB (publ) do?

Immunovia AB (publ) is a leading company in cancer diagnostics based in Lund, Sweden. Founded in 2007 by a group of scientists and entrepreneurs, the company specializes in the development, production, and marketing of diagnostic tests. Immunovia aims to develop innovative and reliable methods for early cancer detection to improve the progress and quality of life for cancer patients. The company's business model is based on research and development of state-of-the-art diagnostic tests, which are distributed worldwide through a network of partners. Immunovia collaborates closely with academic institutions, medical centers, and hospitals to promote research activities and conduct clinical studies. The company's goal is to develop biomarker-based tests for early cancer detection to increase patient survival rates. Immunovia operates in various fields, including pancreatic cancer diagnosis, colorectal cancer diagnosis, lupus diagnosis, and general cancer diagnostics. The company has developed products based on its diagnostic tests, such as the IMMray™ PanCan-d Test for pancreatic cancer diagnosis, IMMray™ Colon Test for colorectal cancer diagnosis, IMMray™ Lupus Test for lupus diagnosis, and IMMray™ Cancer-Screening Test for general cancer diagnostics. Immunovia actively collaborates with various partners, including strategic partnerships with leading biotechnology and pharmaceutical actors, to develop advanced diagnostic products. The company also has a strong financial base to fund its research activities and clinical studies. Overall, Immunovia is dedicated to developing innovative diagnostic tests for early cancer detection and is considered one of the leading players in the cancer diagnostics industry. Immunovia AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Immunovia AB (publ)'s Equity

Immunovia AB (publ)'s equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immunovia AB (publ)'s equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Immunovia AB (publ)'s equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Immunovia AB (publ)'s equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Immunovia AB (publ)’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Immunovia AB (publ) Stock

What is the equity of Immunovia AB (publ) this year?

Immunovia AB (publ) has equity of 66.99 M SEK this year.

What was the equity of Immunovia AB (publ) compared to the previous year?

The equity of Immunovia AB (publ) has increased/decreased by -72.52% decreased compared to the previous year.

What impact does a high equity have on investors of Immunovia AB (publ)?

A high equity is advantageous for investors of Immunovia AB (publ) as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Immunovia AB (publ)?

A low equity can be a risk for investors of Immunovia AB (publ), as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Immunovia AB (publ) affect the company?

An increase in equity of Immunovia AB (publ) can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Immunovia AB (publ) affect the company?

A reduction in equity of Immunovia AB (publ) can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Immunovia AB (publ)?

Some factors that can affect the equity of Immunovia AB (publ) include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Immunovia AB (publ) so important for investors?

The equity of Immunovia AB (publ) is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Immunovia AB (publ) take to change the equity?

To change equity, Immunovia AB (publ) can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Immunovia AB (publ) pay?

Over the past 12 months, Immunovia AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunovia AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Immunovia AB (publ)?

The current dividend yield of Immunovia AB (publ) is .

When does Immunovia AB (publ) pay dividends?

Immunovia AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunovia AB (publ)?

Immunovia AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Immunovia AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunovia AB (publ) located?

Immunovia AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunovia AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunovia AB (publ) from 7/2/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did Immunovia AB (publ) pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Immunovia AB (publ) in the year 2023?

In the year 2023, Immunovia AB (publ) distributed 0 SEK as dividends.

In which currency does Immunovia AB (publ) pay out the dividend?

The dividends of Immunovia AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunovia AB (publ)

Our stock analysis for Immunovia AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunovia AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.